Androgenetic alopecia
Conditions
Interventions
Acupoint catgut embedding group:Basic Treatment: According to the 2019 Chinese Guidelines for the Diagnosis and Treatment of Androgenetic Alopecia, both groups of subjects received topical application
control group:Basic Treatment: According to the 2019 Chinese Guidelines for the Diagnosis and Treatment of Androgenetic Alopecia, both groups of subjects received topical application of 5% minoxidil t
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Agree to follow the experimental treatment plan and visit plan, voluntarily join the group, and sign the informed consent in writing; 2. Male, aged 18-60 years; 3. Clinical diagnosis of androgenetic alopecia. Refer to the ' expert consensus on the diagnosis and treatment of androgenic alopecia with integrated traditional Chinese and Western medicine ' (Zhao Junying, Zuo Yagang, Li Hang, etc.). Expert consensus on the diagnosis and treatment of androgenetic alopecia by integrated traditional Chinese and Western medicine [ J ].Journal of clinical and experimental medicine, 2021, 20 (17): 1902-1905.), forehead hairline retroposition and / or progressive reduction and thinning of hair on the top of the head; 4. The severity of alopecia was classified as grade III, III vertex, or IV according to Hamilton-Norwood classification; 5. The subjects were willing to maintain the same hair style, hair color and hair length at each follow-up.
Exclusion criteria
Exclusion criteria: 1. Scalp local swelling, ulceration, infection and other skin lesions; 2. Those who are allergic to materials such as embedding needles and threads, and intolerant to treatment forms; 3. Other systemic diseases and various causes of subcutaneous tissue absorption, repair function is low; 4. Patients who had used topical drugs for 2 weeks or more in the first 3 months before screening ( including corticosteroid, estrogen, traditional Chinese medicine preparations, etc. ) that may interfere with the evaluation of efficacy; 5. Screening patients who had taken androgen replacement therapy, immunosuppressive agents, topical minoxidil and other drugs that may interfere with the evaluation of efficacy within the previous 12 months; 6. Patients who received autologous platelet-rich plasma or received chemotherapy or cytotoxic agents within 12 months before screening, and patients who received scalp radiation and / or low-energy laser or scalp surgery within 12 months before screening; 7. Can not adhere to the follow-up; 8. Any other situation that the researchers think is not suitable to participate in the experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TAHC, Target Area Hair Counts (The average change between 24 weeks of treatment and baseline); | — |
Secondary
| Measure | Time frame |
|---|---|
| HGA, Hair growth assessment;TAHC, Target Area Hair Counts (The average change between 12 weeks of treatment and baseline);Non-vellus hair diameter (TAHW) in the target area (changes from baseline at 12 and 24 weeks of treatment);Sex hormone levels (changes from baseline at 24 weeks of treatment);Likert Overall Recovery Self-Rating;Evaluation of participants’ Satisfaction;Dermatology Quality of Life Index (DLQI);Center for Epidemiologic Studies Depression Scale (CES-D);Visual Analog Scale (VAS); | — |
Countries
China
Contacts
Public ContactWang Lei
China-Japan Friendship Hospital
Outcome results
None listed